Hospital Cohort Will Test Whether Biliary Disease Tracks With Colorectal Adenoma Risk
A large retrospective cohort in eastern China is examining whether cholecystectomy and other biliary tract diseases are linked to a higher detection risk of colorectal adenoma. The protocol uses hospital information systems, ultrasound records, endoscopy reports, pathology data, operative records, laboratory files, and electronic medical charts to reconstruct exposure history before or at the time of the first qualifying colonoscopy.
The study is anchored in a biologically plausible question. Removal of the gallbladder alters bile storage and delivery, and chronic biliary tract disease can reshape bile acid circulation, intestinal exposure to digestive metabolites, and the microbial environment of the colon. Those pathways matter because adenoma formation begins long before invasive cancer and is strongly tied to the mucosal milieu that promotes epithelial proliferation, dysplasia, and serrated pathway change.
Why Biliary History May Matter at the Colonoscopy Stage
The cohort is designed to compare patients with prior or concurrent biliary exposure against those without such a history. Investigators plan to evaluate not only the presence of adenomas but also more advanced lesions, including advanced adenoma, high-grade intraepithelial neoplasia, adenoma carcinogenesis, and colorectal cancer. In practice, this creates a risk-stratification question for endoscopists: does biliary disease identify a subgroup in whom neoplasia is more likely to be found on colonoscopy, and should surveillance intensity change as a result?
A single sentence captures the core clinical stakes: the study is not merely counting polyps, but testing whether prior biliary pathology shifts the yield of colonoscopic screening.
The rationale extends beyond anatomy. Bile acids interact with colonic mucosa and the microbiome, and persistent changes in that signaling network could reasonably influence adenoma burden or lesion severity. If the association proves strong, it may support more selective colonoscopy follow-up in patients with a biliary history. If the signal is weak or absent, the findings could help avoid unnecessary procedures triggered by a presumed but unproven cancer link.
Retrospective Real-World Design Across Multiple Hospitals
This is a retrospective observational cohort study, not an interventional trial. The dataset spans adult patients treated at Nanjing First Hospital, Nanjing Hospital of Chinese Medicine, Wuhu Hospital of Traditional Chinese Medicine, Sir Run Run Hospital of Nanjing Medical University, and Yangzhou Hospital of Traditional Chinese Medicine. The study window runs from January 2015 through December 2025, with the actual enrollment count listed as 8,450.
Eligibility is intentionally broad on age and sex, but narrow on data quality. Participants must be at least 18 years old and must have undergone at least one biliary ultrasound exam and at least one colonoscopy or pan-colonoscopy at the participating hospitals. Reports had to contain enough information to determine exposure and outcome status, and patient matching had to be reliable through unique identifiers and related hospital records.
The exclusions are clinically important because they strip away conditions that would distort baseline adenoma risk. Patients with prior confirmed colorectal cancer, inflammatory bowel disease, hereditary colorectal cancer syndromes such as familial adenomatous polyposis or Lynch syndrome, major colorectal resection, inadequate bowel preparation, or an incomplete colonoscopy were removed from the analytic framework. Records lacking key exposure or outcome data were also excluded.
Adenoma Detection Will Be the Primary Endpoint
The main endpoint is pathologically confirmed colorectal adenoma at the baseline colonoscopy, defined broadly to include tubular adenoma, tubulovillous adenoma, villous adenoma, traditional serrated adenoma, adenoma with low-grade intraepithelial neoplasia, and adenoma with high-grade intraepithelial neoplasia. This is a sensible endpoint because pathology confirmation reduces the noise that often clouds retrospective endoscopy studies, where visual impressions alone can overstate or understate neoplastic burden.
Adenoma detection is clinically meaningful because it sits upstream of colorectal cancer prevention. Small differences in adenoma yield can translate into real differences in surveillance burden, referral decisions, and follow-up intervals when they are applied to a hospital population at scale.
The study also plans subgroup work by biliary disease subtype, time interval after cholecystectomy, and adenoma location. Those analyses may be especially revealing. Proximal and distal colon lesions do not always behave the same way, and exposure timing could matter if bile acid physiology changes over months or years after surgery rather than immediately afterward.
What the Dataset Can and Cannot Prove Right Now
The protocol is strong on scope and data integration, but it remains an observational design. No intervention is being assigned, and no treatment effect can be inferred in the causal sense. Associations may be influenced by referral patterns, imaging frequency, symptom burden, metabolic comorbidity, or other differences between patients who undergo biliary surgery or biliary imaging and those who do not.
Even so, the real-world structure gives the study a practical edge. Because the dataset is built from routine care, it captures exactly the kind of patients clinicians see in hospital practice: adults with mixed biliary histories, variable endoscopic indications, and pathology-confirmed findings rather than idealized trial eligibility. That makes the eventual signal, whether positive or null, directly relevant to screening decisions.
The completion timeline also matters. Primary completion is listed for December 2025, with study completion expected in December 2026. Results are not posted yet, so the current value of the record lies in the clinical question it poses and the rigor of the data architecture behind it.
Screening Strategy May Shift If the Association Holds
If cholecystectomy or specific biliary disorders are associated with a higher adenoma burden, colonoscopy triage could become more precise for patients with a biliary history. Gastroenterologists might treat prior biliary surgery as one more piece of risk context when deciding who deserves closer follow-up after an initial exam. If the analysis does not show a clear link, the result would argue against expanding surveillance on the basis of biliary history alone.
The practical consequence is straightforward. Patients who have undergone cholecystectomy often arrive in clinic with concern that the operation itself may increase colorectal cancer risk; this study is built to determine whether that concern is supported by pathologically confirmed findings rather than assumption.
No outcome data are available yet, and the study’s final value will depend on whether the retrospective signal survives adjustment for the many clinical variables that accompany biliary disease in everyday care. Until then, the protocol stands as a large hospital-based test of whether bile-related pathology leaves a measurable fingerprint on colorectal neoplasia detection.